These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15788670)

  • 1. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.
    Lee WY; Chen HH; Chow NH; Su WC; Lin PW; Guo HR
    Clin Cancer Res; 2005 Mar; 11(6):2222-8. PubMed ID: 15788670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
    Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
    Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
    Lengyel E; Prechtel D; Resau JH; Gauger K; Welk A; Lindemann K; Salanti G; Richter T; Knudsen B; Vande Woude GF; Harbeck N
    Int J Cancer; 2005 Feb; 113(4):678-82. PubMed ID: 15455388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting.
    Koh YW; Lee HJ; Ahn JH; Lee JW; Gong G
    Pathol Res Pract; 2014 Aug; 210(8):494-500. PubMed ID: 24814255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
    Tokatli F; Altaner S; Uzal C; Ture M; Kocak Z; Uygun K; Bilgi S
    Exp Oncol; 2005 Jun; 27(2):145-9. PubMed ID: 15995634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
    Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
    Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
    Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
    J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and mutational status of RON in neoplastic lesions of the breast: analysis of MSP/RON signaling in ductal carcinoma in situ and invasive ductal carcinoma.
    Ren X; Daa T; Yada N; Kashima K; Fujitomi Y; Yokoyama S
    APMIS; 2012 May; 120(5):358-67. PubMed ID: 22515290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
    Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
    Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
    González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
    Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of cancer-related oncoprotein expression as prognostic factors in breast-cancer with one to three axillary lymph nodes positive].
    Zhang G; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
    Gan To Kagaku Ryoho; 1996 Mar; 23 Suppl 1():66-74. PubMed ID: 8702314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.
    Maggiora P; Lorenzato A; Fracchioli S; Costa B; Castagnaro M; Arisio R; Katsaros D; Massobrio M; Comoglio PM; Flavia Di Renzo M
    Exp Cell Res; 2003 Aug; 288(2):382-9. PubMed ID: 12915129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
    Castro NE; Lange CA
    Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
    Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
    Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression.
    Beviglia L; Matsumoto K; Lin CS; Ziober BL; Kramer RH
    Int J Cancer; 1997 Jun; 74(3):301-9. PubMed ID: 9221809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.